{
    "laboratory_examinations": [
        {
            "procedure_name": "Forced Expiratory Volume in 1 second (FEV1)",
            "date": "Not specified",
            "findings": "Baseline FEV1 was 59% of predicted normal value.",
            "changes_over_time": "FEV1 values progressively increased during treatment, reaching reference normal values (up to 98%) after 4 months."
        },
        {
            "procedure_name": "Skin Prick Test to Wheat Flour and Alpha-Amylase",
            "date": "After 6 months of omalizumab treatment.",
            "findings": "Skin prick test revealed the absence of wheal to wheat flour and alpha-amylase.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Asthma Control Test (ACT)",
            "date": "Beginning of treatment and then every month.",
            "findings": "Initial ACT score was 11, increased up to 25 at the fourth month.",
            "changes_over_time": "ACT score persisted without any change after reaching 25."
        },
        {
            "procedure_name": "Juniper Asthma Quality of Life Questionnaire",
            "date": "Beginning of treatment and after 6 months.",
            "findings": "Remarkable improvement of all individual domains of QoL.",
            "changes_over_time": "Not specified."
        }
    ]
}